Discovering targeted
medicines

Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis

Zelasudil
(RXC007, ROCK2 selective)

Zelasudil
(RXC007, ROCK2 selective)

Zelasudil is a clinical stage, highly selective and orally available ROCK2 inhibitor being developed for the treatment of idiopathic pulmonary fibrosis and fibrotic diseases.

RXC008
(GITR Inhibitor)

RXC008
(GITR Inhibitor)

RXC008 is a GI-targeted ROCK1/2 inhibitor being developed for the treatment of fibrostenotic Crohn’s disease.

Zamaporvint
(RXC004, Porcupine Inhibitor)

Zamaporvint
(RXC004, Porcupine Inhibitor)

Zamaporvint is a clinical stage, highly potent and selective, orally active once-daily Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand driven cancer.

Drug discovery with a strong track record

Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is an opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need. We have built an attractive portfolio of assets and have a strong track record of drug discovery having delivered five molecules to clinical stage development. Our focus is on advancing our differentiated ROCK portfolio which includes our lead asset, zelasudil (RXC007), a next-generation, selective ROCK2 inhibitor for the treatment of interstitial lung diseases and RXC008, a potential first-in-class GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease. Our oncology pipeline is led by zamaporvint (RXC004), a Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy; and our world-class drug discovery engine is advancing a pipeline of research programmes and collaborations in both fibrotic diseases and oncology.

Our values

At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.

Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need.

Our five core company values that underpin everything we do: